|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,450.00 JPY | +2.58% |
|
+3.58% | -4.51% |
Business description: Eisai Co., Ltd.
Number of employees: 10,543
Sales by Activity: Eisai Co., Ltd.
| Fiscal Period: March | 2022 (JPY) | 2023 (JPY) | 2024 (JPY) | 2025 (JPY) | 2026 (JPY) |
|---|---|---|---|---|---|
Pharmaceutical Business - Americas | 17TCr | 21TCr | 23TCr | 28TCr | 30TCr |
Pharmaceutical Business - Japan (Including Pharmaceutical Business - OTC and Others) | - | - | 22TCr | 22TCr | 23TCr |
Pharmaceutical Business - China | 11TCr | 11TCr | 11TCr | 12TCr | 13TCr |
Pharmaceutical Business - EMEA | 5.93TCr | 7.22TCr | 7.6TCr | 7.94TCr | 8.15TCr |
Pharmaceutical Business - East Asia Global South | 5.06TCr | 4.98TCr | 5.42TCr | 5.96TCr | 6.88TCr |
Pharmaceutical Business - Japan (Excl. Pharmaceutical Business - OTC Drugs) | 21TCr | 22TCr | - | - | - |
Pharmaceutical Business - OTC and Others | 2.38TCr | 2.35TCr | - | - | - |
Other Business | 13TCr | 6TCr | 5.03TCr | 4.04TCr | 1.46TCr |
Geographical breakdown of sales: Eisai Co., Ltd.
| Fiscal Period: March | 2022 (JPY) | 2023 (JPY) | 2024 (JPY) | 2025 (JPY) | 2026 (JPY) |
|---|---|---|---|---|---|
United States (U.S.) | 17TCr | 23TCr | 24TCr | 27TCr | 29TCr |
Japan | 24TCr | 25TCr | 23TCr | 23TCr | 24TCr |
China | 11TCr | 11TCr | 11TCr | 13TCr | 13TCr |
Others | 5.28TCr | 6.02TCr | 6.17TCr | 7.23TCr | 8TCr |
Europe | 13TCr | 8.6TCr | 9.05TCr | 7.43TCr | 7.1TCr |
Americas (Excluding United States) | 5.42TCr | 793.7Cr | 1.06TCr | 1.36TCr | 1.69TCr |
Executive Committee: Eisai Co., Ltd.
| Manager | Title | Age | Since |
|---|---|---|---|
Haruo Naito
CEO | Chief Executive Officer | 78 | 01/06/2003 |
Takuya Oyama
DFI | Director of Finance/CFO | 49 | 01/01/2026 |
Katsutoshi Ido
CTO | Chief Tech/Sci/R&D Officer | 48 | 01/04/2025 |
Makoto Hoketsu
CTO | Chief Tech/Sci/R&D Officer | 57 | 01/04/2023 |
Shin Kato
CMP | Compliance Officer | 54 | 01/06/2024 |
Composition of the Board of Directors: Eisai Co., Ltd.
| Director | Title | Age | Since |
|---|---|---|---|
Haruo Naito
BRD | Director/Board Member | 78 | 01/06/1983 |
Kenta Takahashi
BRD | Director/Board Member | 66 | 14/06/2024 |
Yasushi Okada
BRD | Director/Board Member | 67 | 01/06/2025 |
Fumihiko Ike
CHM | Chairman | 74 | 01/06/2023 |
| Director/Board Member | 61 | 17/06/2022 | |
Hiroyuki Kato
BRD | Director/Board Member | 68 | 17/06/2022 |
Yuko Yasuda
BRD | Director/Board Member | 64 | 01/06/2023 |
Toru Moriyama
BRD | Director/Board Member | 71 | 01/06/2023 |
Kanai Sawaji
BRD | Director/Board Member | 67 | 01/06/2024 |
Ryoko Ueda
BRD | Director/Board Member | 53 | 01/06/2025 |
Holdings: Eisai Co., Ltd.
| Name | Stocks | % | Valuation |
|---|---|---|---|
EISAI CO., LTD. 3.27% | 95,34,400 | 3.27% | 242 M $ |
MATSUKIYOCOCOKARA & CO. 1.12% | 45,45,000 | 1.12% | 67 M $ |
NIHON KOHDEN CORPORATION 0.64% | 10,87,600 | 0.64% | 10 M $ |
COGSTATE LIMITED 2.35% | 39,91,003 | 2.35% | 8 M $ |
INTAGE HOLDINGS INC. 1.48% | 5,98,500 | 1.48% | 6 M $ |
| 3,49,000 | 0.43% | 3 M $ | |
| 5,46,005 | 2.24% | 3 M $ | |
PRISM BIOLAB CO.,LTD 1.35% | 5,00,000 | 1.35% | 443 010 $ |
| 100 | 0% | 3 037 $ |
Company details: Eisai Co., Ltd.
Group companies: Eisai Co., Ltd.
| Name | Category and Sector |
|---|---|
Eisai Ltd. (United Kingdom)
 Eisai Ltd. (United Kingdom) Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products |
Pharmaceuticals: Major
|
Eisai Manufacturing Ltd.
 Eisai Manufacturing Ltd. Pharmaceuticals: MajorHealth Technology Engages in manufacture of pharmaceutical products |
Pharmaceuticals: Major
|
Eisai, Inc.
 Eisai, Inc. Pharmaceuticals: MajorHealth Technology Manufacturers pharmaceutical products |
Pharmaceuticals: Major
|
Other Pharmaceuticals
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.58% | +3.58% | +12.72% | -51.53% | 773.54Cr | |
| -2.73% | -3.51% | +48.62% | +152.87% | 1,05100Cr | |
| -1.67% | -3.18% | +52.00% | +56.75% | 61TCr | |
| -0.44% | +2.14% | +33.88% | +84.04% | 45TCr | |
| -0.75% | -1.46% | +28.32% | +22.33% | 33TCr | |
| -1.52% | -0.95% | +33.38% | +38.39% | 28TCr | |
| -1.70% | -3.54% | +20.26% | +17.88% | 26TCr | |
| -0.58% | +1.78% | -20.89% | -38.37% | 22TCr | |
| -0.58% | +0.21% | +23.55% | +56.94% | 20TCr | |
| -0.80% | +2.60% | +23.09% | +68.71% | 17TCr | |
| Average | -0.19% | +0.84% | +25.49% | +40.80% | 35.83TCr | |
| Weighted average by Cap. | -0.01% | +0.03% | +35.20% | +75.30% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4523 Stock
- Company Eisai Co., Ltd.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition